Nicolas Pereyra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nicolas Pereyra has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Dana V. Devine
Department of Pathology and Laboratory Medicine University of British Columbia Vancouver British Columbia Canada
2 shared publications Alix Ashare
Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA; Section of Pulmonary and Critical Care Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA
1 shared publicationAmanda Wietrzny
Versiti Blood Research Institute, Milwaukee, WI
1 shared publication- Anna Krasnodembskaya
Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, Belfast, UK
1 shared publication - Bernd Giebel
Institute of Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
1 shared publication Brenda Ma
Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC, Canada
1 shared publication
Latest Publications
- Open Access
- 23 June 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (23) , e2501217
Investigation on the Influence of Protein Corona and Platelet Adhesion on Storage Bag Surface on the Platelet Storage Lesion
Platelet transfusion is an indispensable therapy used in contexts ranging from hemorrhagic bleeding to chemotherapy. However, platelet shelf life and quality deteriorate during storage in a process termed the platelet storage lesion (PSL), resulting in chronic shortages globally. The PSL is thought to be partially attributed to the bio‐incompatible polyvinyl chloride (PVC) storage bags that promote protein fouling and platelet adhesion. Developing platelet‐friendly materials is therefore essential for improving platelet storage quality. This study aimed to delineate the contributions of protein adsorption and platelet adhesion to the progression of the PSL. Hydrophilic coatings are screened to identify those which resist protein and platelet adhesion most effectively. These coatings are translated into mini‐platelet bags and tested in long‐term standard blood banking conditions. Significant reductions in platelet adhesion after 7‐day storage do not affect platelet quality. Proteomic characterization of the bag surfaces revealed dynamic changes in the protein coronas on coated and uncoated bag over time, but are uncorrelated with platelet quality. This research demonstrates a method to identify platelet‐compatible coatings suitable for long‐term storage, as well as a novel approach to characterize the surface of blood storage bags.
- 23 June 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (23) , e2501217
Open AccessInvestigation on the Influence of Protein Corona and Platelet Adhesion on Storage Bag Surface on the Platelet Storage Lesion
Platelet transfusion is an indispensable therapy used in contexts ranging from hemorrhagic bleeding to chemotherapy. However, platelet shelf life and quality deteriorate during storage in a process termed the platelet storage lesion (PSL), resulting in chronic shortages globally. The PSL is thought to be partially attributed to the bio‐incompatible polyvinyl chloride (PVC) storage bags that promote protein fouling and platelet adhesion. Developing platelet‐friendly materials is therefore essential for improving platelet storage quality. This study aimed to delineate the contributions of protein adsorption and platelet adhesion to the progression of the PSL. Hydrophilic coatings are screened to identify those which resist protein and platelet adhesion most effectively. These coatings are translated into mini‐platelet bags and tested in long‐term standard blood banking conditions. Significant reductions in platelet adhesion after 7‐day storage do not affect platelet quality. Proteomic characterization of the bag surfaces revealed dynamic changes in the protein coronas on coated and uncoated bag over time, but are uncorrelated with platelet quality. This research demonstrates a method to identify platelet‐compatible coatings suitable for long‐term storage, as well as a novel approach to characterize the surface of blood storage bags.
- Open Access
- 20 January 2025
- Published by Elsevier in Cytotherapy
- Vol. 27 (5) , 581-596
Acute respiratory distress vs healthy lung environments differently affect mesenchymal stromal cell extracellular vesicle miRNAs
- 20 January 2025
- Published by Elsevier in Cytotherapy
- Vol. 27 (5) , 581-596
Open AccessAcute respiratory distress vs healthy lung environments differently affect mesenchymal stromal cell extracellular vesicle miRNAs
- 21 November 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (21) , 2223-2236
Genetic engineering of transfusable platelets with mRNA-lipid nanoparticles is compatible with blood banking practices
Platelets contribute to a variety of physiological processes, including inflammation, sepsis, and cancer. However, because of their primary role in hemostasis, platelet transfusions are largely restricted to managing thrombocytopenia and bleeding. One way to expand the utility of platelet transfusions would be to genetically engineer donor platelets with new or enhanced functions. We have previously shown that lipid nanoparticles containing mRNA (mRNA-LNP) can be used to genetically modify authentic platelets in a nonclinical crystalloid solution. Currently, platelets collected for transfusion are stored in plasma or in plasma supplemented with platelet additive solution (PAS) at supraphysiological concentrations at room temperature, or at 4°C if intended for use in acute hemorrhage. Here, we describe a new plasma-optimized mRNA-LNP for transfecting platelets directly in plasma and plasma supplemented with PAS that is scalable to physiological and supraphysiological platelet concentrations. Transfecting platelets in clinical solutions with mRNA-LNP does not affect aspects of in vitro physiology, and transfected platelets are storable. The compatibility of this transfection system with current clinical practices could enable future mRNA-LNP–based platelet products and cell therapies.
- 21 November 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (21) , 2223-2236
Genetic engineering of transfusable platelets with mRNA-lipid nanoparticles is compatible with blood banking practices
Platelets contribute to a variety of physiological processes, including inflammation, sepsis, and cancer. However, because of their primary role in hemostasis, platelet transfusions are largely restricted to managing thrombocytopenia and bleeding. One way to expand the utility of platelet transfusions would be to genetically engineer donor platelets with new or enhanced functions. We have previously shown that lipid nanoparticles containing mRNA (mRNA-LNP) can be used to genetically modify authentic platelets in a nonclinical crystalloid solution. Currently, platelets collected for transfusion are stored in plasma or in plasma supplemented with platelet additive solution (PAS) at supraphysiological concentrations at room temperature, or at 4°C if intended for use in acute hemorrhage. Here, we describe a new plasma-optimized mRNA-LNP for transfecting platelets directly in plasma and plasma supplemented with PAS that is scalable to physiological and supraphysiological platelet concentrations. Transfecting platelets in clinical solutions with mRNA-LNP does not affect aspects of in vitro physiology, and transfected platelets are storable. The compatibility of this transfection system with current clinical practices could enable future mRNA-LNP–based platelet products and cell therapies.